We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pharming Group NV | TG:PHGN | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|
| 0.053 | 5.94% | 0.946 | 120,729 | 22:50:13 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.942 | 0.95 | 0.9495 | 0.889 | 0.8945 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 19:31:58 | 740 | 0.941 | EUR |
| Date | Time | Source | Headline |
|---|---|---|---|
| 15/12/2024 | 18:45 | UKREG | Pharming announces public cash offer to the shareholders of Abliva AB |
| 11/12/2024 | 06:00 | UKREG | Pharming announces positive topline data in pediatric clinical trial of.. |
| 24/10/2024 | 05:00 | UKREG | Pharming Group reports third quarter 2024 financial results and provides.. |
| 10/10/2024 | 06:00 | UKREG | Pharming Group to report third quarter 2024 financial results on October 24 |
| 10/10/2024 | 05:00 | UKREG | Pharming Group announces start of Phase II clinical trial of leniolisib for.. |
| 26/9/2024 | 05:00 | UKREG | Pharming announces marketing authorization in the U.K. for Joenja®.. |
| 01/8/2024 | 05:00 | UKREG | Pharming Group reports second quarter and first half 2024 financial results.. |
| 18/7/2024 | 06:00 | UKREG | Pharming Group to report second quarter and first half 2024 financial.. |
Pharming Group NV (PHGN) Share Charts1 Year Pharming Group NV Chart |
|
1 Month Pharming Group NV Chart |
Intraday Pharming Group NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
